425 related articles for article (PubMed ID: 22356440)
1. Exendin-4 ameliorates diabetic symptoms through activation of glucokinase.
Dhanesha N; Joharapurkar A; Shah G; Dhote V; Kshirsagar S; Bahekar R; Jain M
J Diabetes; 2012 Dec; 4(4):369-77. PubMed ID: 22356440
[TBL] [Abstract][Full Text] [Related]
2. Exendin-4 reduces glycemia by increasing liver glucokinase activity: an insulin independent effect.
Dhanesha N; Joharapurkar A; Shah G; Dhote V; Kshirsagar S; Bahekar R; Jain M
Pharmacol Rep; 2012; 64(1):140-9. PubMed ID: 22580530
[TBL] [Abstract][Full Text] [Related]
3. Omeprazole improves the anti-obesity and antidiabetic effects of exendin-4 in db/db mice (-4 db/db)*.
Patel V; Joharapurkar A; Gandhi T; Patel K; Dhanesha N; Kshirsagar S; Dhote V; Detroja J; Bahekar R; Jain M
J Diabetes; 2013 Jun; 5(2):163-71. PubMed ID: 22830490
[TBL] [Abstract][Full Text] [Related]
4. An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis.
Baggio LL; Huang Q; Cao X; Drucker DJ
Gastroenterology; 2008 Apr; 134(4):1137-47. PubMed ID: 18313669
[TBL] [Abstract][Full Text] [Related]
5. Treatment with exendin-4 improves the antidiabetic efficacy and reverses hepatic steatosis in glucokinase activator treated db/db mice.
Dhanesha N; Joharapurkar A; Shah G; Kshirsagar S; Patel V; Patel K; Bahekar R; Jain M
Eur J Pharmacol; 2013 Aug; 714(1-3):188-92. PubMed ID: 23810686
[TBL] [Abstract][Full Text] [Related]
6. Hypoglycemic effect of deoxynojirimycin-polysaccharide on high fat diet and streptozotocin-induced diabetic mice via regulation of hepatic glucose metabolism.
Li YG; Ji DF; Zhong S; Lin TB; Lv ZQ
Chem Biol Interact; 2015 Jan; 225():70-9. PubMed ID: 25446853
[TBL] [Abstract][Full Text] [Related]
7. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice.
Jin CH; Chae SY; Son S; Kim TH; Um KA; Youn YS; Lee S; Lee KC
J Control Release; 2009 Feb; 133(3):172-7. PubMed ID: 18977255
[TBL] [Abstract][Full Text] [Related]
8. Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice.
Patel KN; Joharapurkar AA; Patel V; Kshirsagar SG; Bahekar R; Srivastava BK; Jain MR
Can J Physiol Pharmacol; 2014 Dec; 92(12):975-83. PubMed ID: 25361428
[TBL] [Abstract][Full Text] [Related]
9. The role of clusterin on pancreatic beta cell regeneration after exendin-4 treatment in neonatal streptozotocin administrated rats.
Kaya-Dagistanli F; Ozturk M
Acta Histochem; 2013 Jul; 115(6):577-86. PubMed ID: 23351716
[TBL] [Abstract][Full Text] [Related]
10. Effect of glucagon-like peptide-1(7-36) and exendin-4 on the vascular reactivity in streptozotocin/nicotinamide-induced diabetic rats.
Ozyazgan S; Kutluata N; Afşar S; Ozdaş SB; Akkan AG
Pharmacology; 2005 Jun; 74(3):119-26. PubMed ID: 15746570
[TBL] [Abstract][Full Text] [Related]
11. Combination of omeprazole with GLP-1 agonist therapy improves insulin sensitivity and antioxidant activity in liver in type 1 diabetic mice.
Patel V; Joharapurkar A; Dhanesha N; Kshirsagar S; Detroja J; Patel K; Gandhi T; Patel K; Bahekar R; Jain M
Pharmacol Rep; 2013; 65(4):927-36. PubMed ID: 24145087
[TBL] [Abstract][Full Text] [Related]
12. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice.
Wang Q; Brubaker PL
Diabetologia; 2002 Sep; 45(9):1263-73. PubMed ID: 12242459
[TBL] [Abstract][Full Text] [Related]
13. Normalizing action of exendin-4 and GLP-1 in the glucose metabolism of extrapancreatic tissues in insulin-resistant and type 2 diabetic states.
Moreno P; Nuche-Berenguer B; Gutiérrez-Rojas I; Acitores A; Sancho V; Valverde I; González N; Villanueva-Peñacarrillo ML
J Mol Endocrinol; 2012 Feb; 48(1):37-47. PubMed ID: 22065862
[TBL] [Abstract][Full Text] [Related]
14. Exendin-4 and exercise promotes beta-cell function and mass through IRS2 induction in islets of diabetic rats.
Park S; Hong SM; Sung SR
Life Sci; 2008 Feb; 82(9-10):503-11. PubMed ID: 18237751
[TBL] [Abstract][Full Text] [Related]
15. Effect of 1-[4- [2-(4-bromobenzenesulfonamino) ethyl] phenylsulfonyl]-3-(trans-4-methylcyclohexyl)urea (I4), a new synthetic sulfonylurea compound, on glucose metabolism in vivo and in vitro.
Wu GZ; Hong G; Zhang WP; Zhang HB
Arzneimittelforschung; 2009; 59(11):550-6. PubMed ID: 20066963
[TBL] [Abstract][Full Text] [Related]
16. Exendin-4 improves hepatocyte injury by decreasing proliferation through blocking NGF/TrkA in diabetic mice.
Gezginci-Oktayoglu S; Sacan O; Yanardag R; Karatug A; Bolkent S
Peptides; 2011 Feb; 32(2):223-31. PubMed ID: 21055431
[TBL] [Abstract][Full Text] [Related]
17. Effects of bis(alpha-furancarboxylato)oxovanadium(IV) on glucose metabolism in fat-fed/streptozotocin-diabetic rats.
Niu Y; Liu W; Tian C; Xie M; Gao L; Chen Z; Chen X; Li L
Eur J Pharmacol; 2007 Oct; 572(2-3):213-9. PubMed ID: 17651728
[TBL] [Abstract][Full Text] [Related]
18. Hypoglycemic effect of a novel dialysed fenugreek seeds extract is sustainable and is mediated, in part, by the activation of hepatic enzymes.
Vijayakumar MV; Bhat MK
Phytother Res; 2008 Apr; 22(4):500-5. PubMed ID: 18338783
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of GLP-1 and exendins action upon glucose transport and metabolism in type 2 diabetic rat skeletal muscle.
Arnés L; González N; Tornero-Esteban P; Sancho V; Acitores A; Valverde I; Delgado E; Villanueva-Peñacarrillo ML
Int J Mol Med; 2008 Jul; 22(1):127-32. PubMed ID: 18575785
[TBL] [Abstract][Full Text] [Related]
20. Differential target molecules for toxicity induced by streptozotocin and alloxan in pancreatic islets of mice in vitro.
Gai W; Schott-Ohly P; Schulte im Walde S; Gleichmann H
Exp Clin Endocrinol Diabetes; 2004 Jan; 112(1):29-37. PubMed ID: 14758569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
